No annual revenue total was found in ALDEYRA THERAPEUTICS, INC.'s SEC filings.
Aldeyra Therapeutics, Inc. (ALDX) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Sep 30, 2026 it held $41.0 million in cash and investments and $458,698 in total debt.
Revenue
—
Net income (TTM)
$-19.13M
+55.7% vs year-ago TTM
Operating cash flow (TTM)
$-19.12M
+52.3% vs year-ago TTM
Free cash flow
$-30.33M
+46.5% vs prior year
EPS (TTM)
$-0.32
+56.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
60.18M
+0.8% vs prior year
Net cash
$40.52M
as of Sep 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ALDX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Concord, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1341235
- Former names
- Aldexa Therapeutics, Inc. (until Mar 4, 2014); Neuron Systems Inc (until Aug 1, 2008)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$35.3M | -$60.1M | -$42.8M | -$62.7M | -$56.2M |
| Net income | -$33.8M | -$55.9M | -$37.5M | -$62.0M | -$57.8M |
| Diluted EPS | -$0.56 | -$0.94 | -$0.64 | -$1.06 | — |
| Operating cash flow | -$33.3M | -$43.2M | -$30.3M | -$56.6M | -$42.6M |
| Free cash flow | — | — | -$30.3M | -$56.7M | -$42.6M |
| Total assets | $72.1M | $104.6M | $148.3M | $181.3M | $233.1M |
| Total liabilities | $27.8M | $33.6M | $28.5M | $30.3M | $27.4M |
| Stockholders' equity | $44.3M | $71.0M | $119.8M | $151.0M | $205.7M |
| Cash and investments | $70.0M | $101.2M | $0 | $174.3M | $229.8M |
| Total debt | $15.6M | $15.6M | $15.8M | $16.6M | $16.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 29, 2026 | Sep 29, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement
|
Jul 30, 2026 | Jul 28, 2026 |
| 8-K |
Current report
Other events
|
Jul 15, 2026 | Jul 14, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results, Regulation FD disclosure
|
Jun 10, 2026 | Jun 9, 2026 |
All 647 Aldeyra Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.